Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Selexipag

FDA-approved product (tablet, oral), marketed as Selexipag, Uptravi.

Registered studies
41
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Selexipag
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Idiopathic and/or familial pulmonary arterial hypertension
  • Idiopathic pulmonary arterial hypertension
  • Pulmonary arterial hypertension
  • Pulmonary hypertension
  • Recurrent thrombophlebitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
FDA pharmacologic class
Prostacyclin Receptor Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

41registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Selexipag in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Selexipag with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO)

    NCT07700303 · start 2026-09-30

    Registered record
    Registry ID
    NCT07700303
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    Discontinuation of parenteral prostacyclins analogues or selexipag
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-09-30
    Completion
    2030-03-30
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionDiscontinuation of parenteral prostacyclins analogues or selexipag
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag

    NCT07759804 · start 2026-09

    Registered record
    Registry ID
    NCT07759804
    Conditions
    Pulmonary Arterial Hypertension (PAH)
    Interventions
    LIQ861 (treprostinil) inhalation powder
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2027-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension (PAH)
    InterventionLIQ861 (treprostinil) inhalation powder
    PhasePhase 4
    Registry statusNot yet recruiting

  • Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension

    NCT07713914 · start 2026-07-22

    Registered record
    Registry ID
    NCT07713914
    Conditions
    Pulmonary Arterial Hypertension (PAH)
    Interventions
    Prostacyclin Pathway Agent; Sildenafil Dose Optimization
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-07-22
    Completion
    2028-12-31
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension (PAH)
    InterventionProstacyclin Pathway Agent; Sildenafil Dose Optimization
    PhasePhase 4
    Registry statusRecruiting

  • Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets

    NCT07694128 · start 2026-04-08

    Registered record
    Registry ID
    NCT07694128
    Conditions
    Arterial Hypertension (PAH)
    Interventions
    Selexipag Film Coated Tablets (T1); Selexipag Film Coated Tablets (T2); Uptravi® (selexipag) film coated tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2026-04-08
    Completion
    2026-06-22
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Hypertension (PAH)
    InterventionSelexipag Film Coated Tablets (T1); Selexipag Film Coated Tablets (T2); Uptravi® (selexipag) film coated tablets
    PhasePhase 1
    Registry statusCompleted

  • Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension

    NCT07356375 · start 2026-03-01

    Registered record
    Registry ID
    NCT07356375
    Conditions
    Pulmonary Arterial Hypertension (PAH)
    Interventions
    Selexipag
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-03-01
    Completion
    2026-12-31
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension (PAH)
    InterventionSelexipag
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension

    NCT07453030 · start 2026-03-01

    Registered record
    Registry ID
    NCT07453030
    Conditions
    Pulmonary Arterial Hypertension (PAH)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-03-01
    Completion
    2027-03-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension (PAH)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)

    NCT06932198 · start 2025-01-09

    Registered record
    Registry ID
    NCT06932198
    Conditions
    Pulmonary Arterial Hypertension (PAH)
    Interventions
    Selexipag Film Coated Tablets; Uptravi® Film Coated Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-01-09
    Completion
    2025-03-25
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension (PAH)
    InterventionSelexipag Film Coated Tablets; Uptravi® Film Coated Tablets
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study

    NCT06753981 · start 2024-12-10

    Registered record
    Registry ID
    NCT06753981
    Conditions
    Arterial Pulmonary Hypertension (PAH)
    Interventions
    Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-12-10
    Completion
    2027-02-14
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Pulmonary Hypertension (PAH)
    InterventionEndothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs
    PhaseNot recorded
    Registry statusRecruiting

  • Pulmonary Hypertension: Intensification and Personalisation of Combination Rx

    NCT05825417 · start 2023-06-14

    Registered record
    Registry ID
    NCT05825417
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    Selexipag; Riociguat; CardioMEMS pulmonary artery pressure monitor; Confirm Rx; Sotatercept
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2023-06-14
    Completion
    2028-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionSelexipag; Riociguat; CardioMEMS pulmonary artery pressure monitor; Confirm Rx +1 more
    PhasePhase 4
    Registry statusActive not recruiting

  • A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

    NCT05179876 · start 2022-05-04

    Registered record
    Registry ID
    NCT05179876
    Conditions
    Hypertension, Pulmonary
    Interventions
    Macitentan; Selexipag; Macitentan/Tadalafil FDC
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-05-04
    Completion
    2030-09-30
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionMacitentan; Selexipag; Macitentan/Tadalafil FDC
    PhasePhase 3
    Registry statusRecruiting

  • A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging

    NCT04435782 · start 2021-07-07

    Registered record
    Registry ID
    NCT04435782
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    JNJ-67896049
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2021-07-07
    Completion
    2023-07-28
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionJNJ-67896049
    PhasePhase 4
    Registry statusTerminated

  • RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists

    NCT05600218 · start 2021-06-01

    Registered record
    Registry ID
    NCT05600218
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    No intervention - Observational study
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-06-01
    Completion
    2024-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionNo intervention - Observational study
    PhaseNot recorded
    Registry statusUnknown

  • A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study

    NCT04565990 · start 2021-05-03

    Registered record
    Registry ID
    NCT04565990
    Conditions
    Hypertension, Pulmonary
    Interventions
    Selexipag
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-05-03
    Completion
    2023-11-10
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionSelexipag
    PhasePhase 3
    Registry statusCompleted

  • A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

    NCT03942211 · start 2021-02-26

    Registered record
    Registry ID
    NCT03942211
    Conditions
    Sarcoidosis-associated Pulmonary Hypertension
    Interventions
    Selexipag; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-02-26
    Completion
    2023-04-19
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoidosis-associated Pulmonary Hypertension
    InterventionSelexipag; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension

    NCT04589390 · start 2020-10-15

    Registered record
    Registry ID
    NCT04589390
    Conditions
    Pulmonary Hypertension; Schistosomiasis
    Interventions
    Selexipag
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-10-15
    Completion
    2022-03-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Hypertension; Schistosomiasis
    InterventionSelexipag
    PhasePhase 2
    Registry statusUnknown